Nanotechnological carriers for cancer chemotherapy: The state of the art

被引:222
作者
Estanqueiro, Marilene [1 ]
Amaral, Maria Helena [1 ]
Conceicao, Jaime [1 ]
Sousa Lobo, Jose Manuel [1 ]
机构
[1] Univ Porto, Fac Pharm, Dept Drug Sci, Lab Pharmaceut Technol, P-4050313 Oporto, Portugal
关键词
Cancer; Anticancer drugs; Liposomes; Micelles; Dendrimers; Nanoparticles; SOLID LIPID NANOPARTICLES; DRUG-DELIVERY-SYSTEM; BIODEGRADABLE POLYMERIC NANOPARTICLES; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-I; TARGETED DELIVERY; POLY(ETHYLENE GLYCOL); ANTICANCER DRUGS; SKIN DELIVERY; ORAL DELIVERY;
D O I
10.1016/j.colsurfb.2014.12.041
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Cancer is a term used for a heterogeneous group of malignant diseases in which abnormal cells divide without control and are able to invade other tissues, resulting in metastasis. According to the last data of World Health Organization the incidence and mortality rates of cancer are high and tend to increase. Chemotherapy is usually used in cancer treatments, but due to the lack of specificity of drugs, is associated to various and damaging side effects that have a severe impact on patients quality of life. Nanotechnology is actually an important area of interest in science and technology, which has been extensively explored during the last decade, particularly in the development of carriers for cytotoxic drugs. These carriers include vesicular and particulate systems such as liposomes, niosomes, transfersomes, ethosomes, micelles, dendrimers, and polymeric, protein and lipid nanoparticles. Polymer-drug conjugates and antibody-drug conjugates have also been studied. The present review is an attempt to contemplate the studied nanocarriers in the field of anticancer drugs delivery, their advantages and disadvantages and future perspectives. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:631 / 648
页数:18
相关论文
共 268 条
  • [1] Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer
    Abouzeid, Abraham H.
    Patel, Niravkumar R.
    Torchilin, Vladimir P.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 464 (1-2) : 178 - 184
  • [2] Mechanisms of phagocytosis in macrophages
    Aderem, A
    Underhill, DM
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 : 593 - 623
  • [3] A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
    Ahn, Hee Kyung
    Jung, Minkyu
    Sym, Sun Jin
    Shin, Dong Bok
    Kang, Shin Myung
    Kyung, Sun Young
    Park, Jeong-Woong
    Jeong, Sung Hwan
    Cho, Eun Kyung
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 277 - 282
  • [4] ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
  • [5] Liposomal drug delivery systems: From concept to clinical applications
    Allen, Theresa M.
    Cullis, Pieter R.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) : 36 - 48
  • [6] Liposomes - Opportunities in drug delivery
    Allen, TM
    [J]. DRUGS, 1997, 54 (Suppl 4) : 8 - 14
  • [7] Efficacy of edelfosine lipid nanoparticles in breast cancer cells
    Angela Aznar, Maria
    Lasa-Saracibar, Beatriz
    Estella-Hermoso de Mendoza, Ander
    Jose Blanco-Prieto, Maria
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 454 (02) : 720 - 726
  • [8] [Anonymous], 2014, CPX 351 AC MYEL LEUK
  • [9] [Anonymous], 2013, DIFF TYP CHEM DRUGS, Vhttp://www.cancer.org/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-types-of-chemo-drugs
  • [10] [Anonymous], CALAA 01 PIP